Combined Utility of 25 Disease and Risk Factor Polygenic Risk Scores for Stratifying Risk of All-Cause Mortality

Risk of All-Cause Mortality

Allison Meisner,[1] Prosenjit Kundu,[1] Yan Dora Zhang,[1,2] Lauren V. Lan,[1] Sungwon Kim,[1] Disha Ghandwani,[1,3] Parichoy Pal Choudhury,[4] Sonja I. Berndt,[4] Neal D. Freedman,[4] Montserrat Garcia-Closas,[4] Nilanjan Chatterjee[1,5,*]

[1]Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205, USA

[2]Department of Statistics, University of Hong Kong, Hong Kong

[3]Indian Statistical Institute, Kolkata, West Bengal, 700108, India

[4]Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, 20892, USA

[5]Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205, USA

*Correspondence to nilanjan@jhu.edu

ABSTRACT

While genome-wide association studies have identified susceptibility variants for numerous

traits, their combined utility for predicting broad measures of health, such as mortality, remains

poorly understood. We used data from the UK Biobank to combine polygenic risk scores (PRS)

for 13 diseases and 12 mortality risk factors into sex-specific composite PRS (cPRS). These

cPRS were moderately associated with all-cause mortality in independent data: the estimated

hazard ratios per standard deviation were 1.10 (95% confidence interval: 1.05, 1.16) and 1.15

(1.10, 1.19) for women and men, respectively. Differences in life expectancy between the top

and bottom 5% of the cPRS were estimated to be 4.79 (1.76, 7.81) years and 6.75 (4.16, 9.35)

years for women and men, respectively. These associations were substantially attenuated after

adjusting for non-genetic mortality risk factors measured at study entry. The cPRS may be

useful in counseling younger individuals at higher genetic risk of mortality on modification of

non-genetic factors.

INTRODUCTION

Genome-wide association studies (GWAS) with increasingly large sample sizes have led to the discovery of thousands of genetic variants associated with individual traits, including complex diseases and risk factors for disease (1). Analyses of polygenicity of a variety of traits (2,3) have further indicated that many individual traits are likely to be associated with thousands to tens of thousands of genetic variants, each with very small effect. Thus, much attention has been paid to the utility of polygenic risk scores (PRS), which represent the genetic burden of a given trait, for developing strategies for risk-based intervention through lifestyle modification (4–8), screening (5,7–12), and medication (5,7,13,14). A PRS for a given trait is typically defined as a weighted sum of a set of germline single-nucleotide polymorphisms (SNPs), where the weight for each SNP corresponds to an estimate of the strength of association between the SNP and the trait (7). Recent studies indicate that while PRS tend to have modest predictive capacity overall, they have the potential to offer substantial stratification of a population into distinct levels of risk for some common diseases such as coronary artery disease (CAD) and breast cancer (4,15).

There is ongoing debate regarding the utility of PRS in clinical practice (16–18). PRS can be more robust and cost-efficient tools for risk stratification than other biomarkers and risk factors. In particular, PRS do not change over time and thus need to be measured only once. Additionally, the risk associated with PRS for different traits appears in many cases to be fairly consistent over an individual's life course (15,19) and time-varying lifestyle and clinical factors tend to act in a multiplicative way on baseline genetic risk (4,6,20,21). Further, if genome-wide genotype and/or sequencing data are available on an individual, the same data can be used to evaluate the PRS for a large number of traits simultaneously. Thus, beyond the use of PRS for

prevention of specific diseases, it is important to evaluate their utility for broad health outcomes,

particularly if PRS are to be utilized in routine health care.

The broad health impact of public health or clinical interventions is often measured in terms of

their impact on all-cause mortality or lifespan (22–25). While a small number of genetic variants

associated with lifespan have been identified (26–28), no study to date has systematically

evaluated the ability of emerging PRS for life-threatening diseases and mortality risk factors to

predict mortality. We used data from the UK Biobank, a large prospective cohort study, to

assess the combined utility of PRS associated with 13 common diseases and 12 established

risk factors for mortality. We used training data to combine the trait-specific PRS into sex-

specific composite PRS (cPRS) that are predictive of all-cause mortality. We then evaluated the

association of these cPRS with all-cause mortality and their ability to stratify mortality risk in

independent test data. We also assessed the degree to which mortality risk associated with the

cPRS was accounted for by mortality risk factors measured at the time of entry into the study,

i.e., middle age for most participants. Finally, we examined the potential clinical use of the

cPRS, namely, counseling individuals at higher genetic risk of mortality on modification of non-

genetic risk factors such as body mass index (BMI) and smoking status.

SUBJECTS AND METHODS

Causes of Death and Mortality Risk Factors

We used the Centers for Disease Control (CDC) Wide-ranging ONline Data for Epidemiologic

Research (WONDER) database to identify the top causes of death (organized by the

International Classification of Diseases (ICD)-10 113 Causes List) in terms of the number of

deaths among non-Hispanic whites in the United States over the age of 40 in 2017, separately

for men and women (29). We then determined the top 10 causes of death with some genetic

basis, i.e., causes for which there is evidence of an association between one or more genetic

variants and disease risk (Table S1). These causes accounted for 70.3% and 71.8% of deaths

among women and men, respectively, in the CDC data.

Several of these causes were very general categories of disease (e.g., "diseases of heart"),

making it difficult to identify relevant trait-specific GWAS. Thus, we identified the specific cause

within these categories associated with the highest number of deaths (with the exception of

"malignant neoplasms"; here, we identified the top four cancers for each sex in terms of the

number of deaths). The final list of diseases was: CAD, COPD, Alzheimer's disease, stroke,

type 2 diabetes, CKD, hypertension, alcoholic liver cirrhosis, Parkinson's disease, pancreatic

cancer, colorectal cancer, lung cancer, breast cancer (women only), and prostate cancer (men

only) (Table S1). These causes of death captured 44.4% and 44.9% of deaths among women

and men, respectively, in the CDC data. The difference between these figures and those cited

above (70.3% and 71.8% for women and men, respectively) are driven largely by deaths from

non-CAD diseases of the heart and deaths from malignant neoplasms not included in our list of

cancers. As our analysis involves UK Biobank data, we also used Office of National Statistics

mortality data (30) to determine the top causes of death in the UK; these were nearly identical to

those identified using the CDC data (Table S1).

Based on government statistics from the UK (31), we further identified major mortality risk

factors that are known to have some genetic component (32,33). We included smoking status,

alcohol consumption, SBP, BMI, total cholesterol, fasting plasma glucose, and eGFR. Beyond

the risk factors highlighted by the UK government statistics, we included LDL cholesterol, HDL

cholesterol, triglycerides, DBP, and sleep duration. In particular, sleep duration was included on

the basis of several studies showing clear links between sleep duration and all-cause mortality

(34–36).

Extraction of SNP Information from the GWAS Catalog and Publicly Available GWAS

To generate a PRS for each disease included in the top causes of death, we used results

published in the NHGRI-EBI GWAS Catalog (37) to identify SNPs associated with the disease.

We downloaded the GWAS Catalog results on March 15, 2019, and selected autosomal

genome-wide significant SNPs (p-value $\leq$ 5 x 10^{-8}). For each disease, we identified one or more

search terms based on the trait names used by the GWAS Catalog, and selected the SNPs

corresponding to these search terms. We then checked several fields of the GWAS Catalog,

such as the source of the data, the study title, and the description of the trait studied, to ensure

that we retained relevant SNPs; in particular, we sought to include results from analyses of

Europeans (or multi-ethnic populations including Europeans) and to exclude studies of

pleiotropic or composite outcomes, studies not of disease susceptibility, studies of children or

pregnant women, studies of a secondary condition in individuals with a primary condition (e.g.,

myocardial infarction in individuals with coronary heart disease), studies of haplotypes or multi-

SNP analyses, and studies of subpopulations (e.g., carriers of a specific genetic mutation; the

only exceptions to this were studies of cirrhosis among alcohol drinkers and studies of COPD

among smokers) or SNP-environment interactions. Importantly, these exclusions mean we

included only GWAS of disease status, rather than GWAS of particular outcomes among

individuals with a given disease, e.g., disease-associated mortality. In the resulting list of SNPs,

there were several cases where the same SNP appeared multiple times for the same disease

trait. In these situations, we kept the result from the largest study (in terms of the number of

cases). The same SNP may appear for multiple traits.

For our analysis, it was important to extract the effect allele, effect size, and effect allele frequency for each SNP. The effect allele and effect size were used to construct the PRS in the UK Biobank, and the effect allele and effect allele frequency were used to check whether the SNP in the UK Biobank was the same as the SNP reported on the GWAS Catalog. For many SNPs on the list we created, some or all of this information was missing in the GWAS Catalog. We sought to fill in this information by consulting the original paper and its supplemental materials, as well as the Ensembl database (38). In situations where we were not able to discern the effect allele, the effect allele frequency, or the effect size of a particular SNP, the SNP was removed from our list.

We applied the same approach for identifying SNPs for each cause of death except for stroke. This is because there are several types of stroke and different studies included in the GWAS Catalog employed definitions of stroke with varying specificity. Thus, we used a recently published stroke PRS (39) instead of using the results available from the GWAS Catalog.

Our approach to identifying SNPs for inclusion in the mortality risk factor PRS differed from the approach described above. In particular, we found that the risk factor phenotypes were typically defined and/or analyzed differently across studies. For instance, smoking behavior could be defined as ever-use of cigarettes (never vs. former/current) or more granularly, incorporating cigarettes per day and duration among ever smokers. As another example, body mass index could be analyzed as a raw measurement, or it could first be rank-transformed. In light of these complications, instead of using the results included in the GWAS Catalog, we used the results from the most recent, largest trait-specific GWAS for which summary data were available (40–45). As above, we selected autosomal genome-wide significant SNPs ($p \leq 5 \times 10^{-8}$) and removed SNPs for which the effect allele, effect size, or effect allele frequency were unavailable. In addition, as variant identifiers (RS IDs) were the primary way of querying the UK

Biobank genotype data (described below), SNPs without RS IDs were removed (this was not an

issue for the GWAS Catalog results).

UK Biobank: Disease and Mortality Data

The UK Biobank is a large cohort study of over 500,000 individuals in the UK (46). The study

enrolled individuals aged 40-69 years between 2006 and 2010 and has followed them since

enrollment. A vast array of information has been collected from these individuals, including

genotype data, anthropometric measurements, and information on lifestyle factors and personal

and family history of disease. Additionally, data from national death and cancer registries are

linked to the UK Biobank data.

We retrieved data on mortality, incident and prevalent disease for the top causes of death, and

mortality risk factor measurements at baseline. The death registry data were available through

November 30, 2016, for the centers in Scotland and January 31, 2018, for the centers in

England and Wales. We determined whether an individual died of a particular disease by

considering the ICD-10 code listed as the primary cause of death (see Table S1 for the codes

used). We used several sources of data to identify incident and prevalent cases of disease for

the top causes of death. In particular, we used cancer registry data (available through October

31, 2015, in Scotland and March 31, 2016, in England and Wales) to determine whether

participants had or experienced the cancers in our list of diseases before (prevalent case) or

after (incident case) study baseline on the basis of ICD-9 and ICD-10 codes (Table S2). For the

non-cancer diseases, we used questionnaire/interview data, hospital episode data (available

through March 31, 2017, in England, October 31, 2016, in Scotland, and February 29, 2016, in

Wales), and death registry data to identify prevalent and incident cases of disease (Table S2).

The exception to this was incident and prevalent diabetes, which were defined based on the

algorithm presented in (47). For SBP and DBP at baseline, two measurements were made for

each; when both of these were non-missing, the average was used. Self-reported intake of

different forms of alcohol was converted into grams of alcohol per day (Table S3).

In all analyses, unless otherwise specified, we adjusted for the first ten genetic principal

components, which were provided by the UK Biobank, in order to account for population

stratification. In addition, all survival models accounted for left truncation by starting the follow-

up interval at study entry. Throughout, we restricted our attention to unrelated participants (third

degree relatives or closer were removed) of white British ancestry, in order to minimize the

influence of population stratification and avoid issues related to clustering of individuals in

families. We further removed individuals who had withdrawn their consent to participate.

Unrelated participants were identified as those who were used by the UK Biobank to compute

the principal components and ancestry was determined by the UK Biobank based on self-report

and principal component analysis. The UK Biobank was approved by the North West Multi-

centre Research Ethics Committee. This research was conducted using the UK Biobank

Resource under Application Number 17712.

Evaluating PRS in the UK Biobank

Imputed genotype data (in the form of allele dosage, i.e., between 0 and 2) for the SNPs

identified above were extracted from the UK Biobank, matching on RS ID if possible and on

chromosome and position otherwise. Non-biallelic SNPs and ambiguous palindromic SNPs (A/T

or C/G SNPs with allele frequencies between 0.4 and 0.6) were removed. To ensure the SNPs

from the UK Biobank were the same as those on our curated list of trait-associated SNPs, the

alleles and allele frequencies were compared (allowing for the possibility of strand flips). SNPs

that did not match the UK Biobank data, i.e., SNPs for which the reported allele frequency and

the allele frequency in the UK Biobank differed by more than 0.15, were removed. Finally, SNPs

in LD were removed via LD clumping, implemented using PLINK with an r^2 cutoff of 0.1 and

based on the reported p-values (from the GWAS Catalog or the publicly available summary

statistics) and the 1000 Genomes European reference panel (48,49). This was done separately

for each disease and risk factor, yielding a list of independent SNPs for each trait. The one

exception was stroke: the SNP list was not pruned because the estimated association

coefficients provided were based on a joint SNP model. The number of SNPs included in each

PRS varied widely, between two SNPs for cirrhosis and 1,458 for BMI (Table S4). In total, our

analysis included 3,941 unique SNPs.

Next, a PRS for each trait was constructed for each participant by weighting the SNP dosage by

the reported log odds ratio (for binary traits) or linear regression coefficient (for continuous

traits):

$$PRS_{i,j} = \sum_{k=1}^{m_j} g_{i,k}\beta_{k,j},$$

where $PRS_{i,j}$ is the PRS value for the ith individual and the jth trait, m_j is the number of SNPs

included in the PRS for the jth trait, $g_{i,k}$ is the genotype dosage for the ith individual and the kth

SNP, and $\beta_{k,j}$ is the log odds ratio or linear regression coefficient for the kth SNP and the jth trait.

Statistical Analysis

All analyses were sex-specific and the PRS were standardized to have unit variance. We first

evaluated the association between each derived PRS and the corresponding trait (i.e., prevalent

disease and incident disease for the disease trait, and measurement at baseline for the mortality

risk factors). For the disease traits, we evaluated the association with incident and prevalent

disease status separately. To evaluate the relationship between each disease PRS and

prevalent disease, we fit a logistic regression model for each disease. We used Poisson models

with robust variance estimation (50) to evaluate the association between each disease PRS and

incident disease among individuals without prevalent disease. For the mortality risk factors, we

used linear regression with robust variance estimation to model the relationship between each

mortality risk factor PRS and the risk factor measurement at baseline. The one exception was

smoking status; since the smoking status PRS was developed based on a GWAS of ever-use of

cigarettes, we defined the smoking status risk factor as ever-use of cigarettes. As this is a

binary variable, we used logistic regression to model the relationship between the smoking

status PRS and ever-use of cigarettes. Since eGFR was not directly available in the UK

Biobank, we calculated eGFR at baseline using the Modification of Diet in Renal

Disease (MDRD) Study equation (51); this mirrors the definition of eGFR used in the GWAS

upon which our eGFR PRS was based (45). All models included adjustment for age at entry, in

addition to the first ten principal components.

We also investigated cause-specific mortality for the diseases included in our top causes of

death. We used Cox proportional hazards models to study the relationship between each

disease PRS and age at death from that disease. Deaths from other causes were treated as

censoring events. We performed these analyses in the full cohort and also among individuals

with and without the disease corresponding to the cause of death being modeled at baseline.

We also evaluated the relationship between each mortality risk factor PRS and mortality due to

each of the causes of death. For all of the analyses related to cause-specific mortality, when

there were not enough deaths to yield stable estimates, estimates are not provided.

Our main analysis involved studying the joint relationship between the 25 PRS and all-cause

mortality. First, we split the data into training (2/3) and test (1/3) sets. Then, in the training data,

all PRS (with the exception of prostate cancer and breast cancer for the female- and male-

specific models, respectively) were included in Cox proportional hazards models of age at

death:

$$\lambda(t|PRS_1, \ldots, PRS_{25}, \boldsymbol{Z}) = \lambda_0(t)\exp(\theta_1 PRS_1 + \cdots + \theta_{25} PRS_{25} + \boldsymbol{\beta}^T \boldsymbol{Z}).$$

In this formula, $\lambda(t|PRS_1, \ldots, PRS_{25})$ denotes the hazard at age t given $PRS_1, \ldots, PRS_{25}$, $\lambda_0(t)$

denotes the baseline hazard at age t, and $\boldsymbol{Z}$ is a vector of the first ten principal components.

Each model yielded a weighted combination of the individual PRS where the weights were the

estimated log HRs from the Cox model, $\hat{\theta}_1 PRS_1 + \cdots + \hat{\theta}_{25} PRS_{25}$; we refer to these sex-specific

weighted combinations as the "composite PRS" (cPRS). These cPRS were then applied to the

test data. In particular, we used a Cox model to evaluate the HR for all-cause mortality per

standard deviation of the cPRS. In addition, we estimated the HR comparing individuals in the

top 5% of the cPRS distribution to those in the middle 20% and the HR comparing individuals in

the bottom 5% to those in the middle 20% in the test data. This was based on quantiles

estimated in the training data. To aid in the interpretation of these results, the estimated HRs

were converted into approximate years of life difference, as done in other studies of survival

(26,33). In addition, we used Harrell's C-index to quantify the discriminatory ability of the cPRS

(52); note that this evaluation did not adjust for principal components.

We undertook a series of additional analyses. First, we evaluated the association between the

cPRS and all-cause mortality in the "healthy" subset of the test data, that is, the test set after

removing individuals with any of the diseases included as a top cause of death at baseline (i.e.,

prevalent cases). We also re-evaluated the association between the cPRS and all-cause

mortality in the test data, adjusting for the mortality risk factors measured at baseline (that is,

BMI, smoking status, alcohol consumption, SBP, DBP, eGFR, total cholesterol, LDL cholesterol,

HDL cholesterol, triglycerides, blood glucose, and sleep duration), removing individuals in the

test data that were missing any of these measurements. All risk factors were included as

continuous variables, with the exception of smoking status, which was included as a binary

variable (ever vs. never use).

Finally, we evaluated the relationship between two major modifiable risk factors, BMI and

smoking status, and absolute risk of mortality for individuals at different levels of polygenic risk.

We estimated the mortality risk for obese individuals (BMI > 30 kg/m^2) and normal weight

individuals (BMI of 18.5-25 kg/m^2) based on Cox proportional hazards models with quintiles of

the cPRS and BMI categories ($\leq$ 18.5 kg/m^2, (18.5-25 kg/m^2], (25-30 km/m^2], > 30 kg/m^2), both

modeled as categorical variables, fit in the test data. Estimates of risk for never smokers and

ever smokers are based on Cox proportional hazards models with quintiles of the cPRS,

modeled as a categorical variable, and an indicator of ever-use of cigarettes, fit in the test data.

These models did not include adjustment for principal components.

All analyses were conducted using R (53), including the rms (54), survival (55), ggplot2 (56),

and sandwich (57,58) packages. We report 95% confidence intervals throughout.

RESULTS

UK Biobank: Disease, Mortality, and Genotype Data

After removing individuals who were related, were not of British ancestry, or had withdrawn their

consent to participate, our dataset included 337,138 participants, including 181,027 women and

156,111 men (Tables 1 and S5). There were 13,610 deaths (4.0%) with 5,250 among women

(2.9%) and 8,360 among men (5.4%). The diseases included in the top causes of death

accounted for 45.9% of the deaths in women and 45.5% of the deaths in men in the UK

Biobank. Notably, very few deaths in the UK Biobank were attributed to type 2 diabetes, which

appears to be due to many more deaths in the UK Biobank having type 2 diabetes listed as a

secondary cause of death as opposed to the primary cause.

Constructing and Evaluating the Trait-Specific PRS in the UK Biobank

As anticipated, the trait-specific PRS tended to be moderately to strongly associated with the

corresponding disease or risk factor (Figure S1 and Table S6). The strongest associations for

the disease traits (odds ratios or relative risks of at least 1.5 per standard deviation (SD)) were

observed for Alzheimer's disease (incident disease only), type 2 diabetes, breast cancer in

women, prevalent CAD in men, cirrhosis in men, and prostate cancer in men.

We observed that the PRS for each disease was generally at least moderately associated with

death from that disease (Figure 1), with the association being strongest for Alzheimer's disease

(hazard ratio (HR) per SD: 1.86 (95% confidence interval: 1.42, 2.42) in women; 2.01 (1.52,

2.65) in men), CAD (1.51 (1.34, 1.69) in women; 1.48 (1.40, 1.57) in men), breast cancer in

women (1.51 (1.40, 1.63)), prostate cancer in men (1.68 (1.54, 1.84)), and cirrhosis in men

(1.49 (1.03, 2.16)). In general, the PRS were stronger predictors of cause-specific mortality

among individuals without prevalent disease than they were among individuals with prevalent

disease (Figure S2); this indicates the PRS were typically more strongly associated with disease

onset than with prognosis.

We found that the PRS for BMI was at least moderately associated with mortality related to CAD

(primarily in men), COPD (among women), hypertension (among men), lung cancer (among

women), pancreatic cancer (among women), Parkinson's disease (among women), and stroke

(among women) (Figures S3 and S4). The PRS for smoking was weakly associated with

mortality due to CAD (among men) and moderately associated with mortality due to COPD

(primarily in men) and lung cancer. The PRS for LDL cholesterol was strongly associated with

mortality related to Alzheimer's disease (among men) and COPD (among women) and

moderately associated with mortality due to CAD (primarily in men). The PRS for total

cholesterol was strongly positively associated with mortality due to Alzheimer's disease

(primarily in men) and COPD (among women), moderately positively associated with mortality

related to CAD (among men), and moderately negatively associated with mortality due to

pancreatic cancer (among men). The PRS for triglycerides was strongly negatively associated

with mortality from stroke among men. The PRS for alcohol consumption was moderately

positively associated with mortality due to CAD, primarily among men.

We found that several PRS were modestly associated with all-cause mortality, with some

differences between men and women (Figure 2). The PRS for BMI was modestly associated

with risk of all-cause mortality for both women (HR per SD: 1.07 (1.04, 1.10)) and men (1.08

(1.05, 1.10)). In addition, the PRS for smoking status, Alzheimer's disease, LDL cholesterol, and

lung cancer were modestly associated with all-cause mortality in both sexes. The PRS for

breast cancer and prostate cancer were modestly associated with all-cause mortality in women

and men, respectively. Among men, the PRS for CAD, cirrhosis, DBP, HDL cholesterol, SBP,

stroke, total cholesterol, triglycerides, type 2 diabetes, and alcohol consumption were modestly

associated with all-cause mortality; notably, the PRS for HDL cholesterol and triglycerides were

both negatively associated with all-cause mortality. In general, the estimated associations

tended to be stronger in men than in women.

Constructing and Evaluating the Composite PRS in the UK Biobank

The training data used the construct the cPRS included 224,756 participants, among them

120,719 women and 104,037 men (Table 1). There were 9,106 deaths in the training data with

3,530 in women and 5,576 in men. Correspondingly, the test data used to evaluate the cPRS

included 112,382 individuals (60,308 women and 52,074 men) and 4,504 deaths (1,720 among

women and 2,784 among men).

The cPRS were moderately associated with all-cause mortality in the test data (HR per SD: 1.10

(1.05, 1.16) in women, 1.15 (1.10, 1.19) in men; see Table 2 and Figure S5). However, the

cPRS were able to identify substantial fractions of the population that have meaningfully

elevated and reduced mortality risk, particularly among men (Table 2 and Figure 3). The

estimated difference in life expectancy between the top and bottom 5% of the cPRS distribution

was 4.79 (1.76, 7.81) years in women and 6.75 (4.16, 9.35) years in men. The overall

discriminatory capacity of the cPRS, measured by Harrell's C-index (52), was small: 0.525 in

women and 0.536 in men. These are comparable to the values for several strong risk factors for

mortality, including BMI (0.532 in women, 0.530 in men), smoking status (0.562 in women,

0.574 in men), and alcohol consumption (0.509 in women, 0.547 in men).

When we evaluated the cPRS in the "healthy" subset of the test data, the estimated

associations between the cPRS and all-cause mortality were fairly similar to the results from the

main analysis (Table S7). Separately, when we adjusted for the mortality risk factors measured

at baseline, the association between the cPRS and all-cause mortality was markedly attenuated

for both sexes (Table 2). These results indicate that a substantial fraction (40.7% for women

and 32.5% for men) of the association between the cPRS and all-cause mortality was

accounted for by these risk factors, which are (to varying degrees) heritable traits. After

controlling for the measured risk factors, the difference in life expectancy between the top 5%

and the bottom 5% of the cPRS distribution was estimated to be 2.99 (-1.28, 7.26) years in

women and 5.39 (2.18, 8.60) years in men.

Finally, we evaluated the relationship between BMI and smoking status and absolute risk of

mortality for individuals at different levels of polygenic risk (Figure 4). We observe that the

estimated 10-year absolute risk of mortality for a 60-year-old woman in the top 20% of the cPRS

distribution who is obese is 0.044. This is 38% higher than the estimated risk for a woman in the

top 20% of the cPRS distribution who is not obese. Similarly, the estimated risk for a 60-year-old

woman in the top 20% of the cPRS distribution who is a current or former is 64% higher than for

a woman who has never smoked (0.046 vs. 0.028). Likewise, for a 60-year-old man, the

estimated 10-year risk of mortality is 24% higher if the man is obese as opposed to normal

weight (0.087 vs. 0.070) and the estimated risk is 81% higher if the man is a current or former

smoker relative to a man who has never smoked (0.087 vs. 0.048). These differences highlight

the potential importance of lifestyle modification even among those at high genetic risk.

Furthermore, in most of these examples, the estimated risk for an individual who is in the top

20% of the cPRS distribution but who has a favorable risk factor profile is below the estimated

risk for an individual in the middle 20% of the cPRS distribution, i.e., someone at moderate

genetic risk (0.032 in women and 0.059 in men).

DISCUSSION

Analyses using a large dataset from the UK Biobank indicate that sex-specific composite PRS

(cPRS) for all-cause mortality have fairly modest predictive capacity overall. However, there is

evidence that the cPRS could identify substantial fractions of the population with notably

elevated and reduced risk of all-cause mortality due to the genetic risk accumulated across

many variants. Importantly, our results also show that a substantial proportion of the association

between the cPRS and mortality was accounted for by mortality risk factors measured in middle

age. These findings suggest that those individuals at high genetic risk of mortality may derive

substantial benefit from modification of lifestyle factors; in particular, the cPRS could be useful in

counseling individuals at high genetic risk on possible lifestyle choices that are associated with

lower mortality risk.

A previous study evaluated the utility of 707 SNPs identified from GWAS of 125 diseases and

risk factors for estimating mortality risk (32). This study developed a PRS directly from the

individual SNPs, counting only the number of detrimental or protective alleles across the

variants (i.e., without weighting the SNPs by the strength of association). In a combined analysis

of men and women from two studies of northern European populations, the study reported a

10% higher risk of mortality between individuals in the 4th versus 1st quartile of the resulting

PRS. In contrast, in the current study, we focus on a limited number of the most important

causes of and risk factors for mortality, and build cPRS for mortality based on the underlying

PRS. Our cPRS, although evaluated in a different population, appears to provide greater

mortality risk stratification (HR for 4th vs. 1st quartile = 1.29 (1.13, 1.48) in women; 1.38 (1.24,

1.53) in men). These differences may be due to the incorporation of a larger number of SNPs

emerging from more recent GWAS as well as the weighting of individual SNPs to account for

their association with the individual diseases and risk factors in our analysis.

Several recent studies (26,59–62) have investigated the association of individual genetic

variants and PRS with parental lifespans due to the increased power of these analyses relative

to analyses of lifespan in genotyped individuals. Two large GWAS of parental lifespan, both

including data from the UK Biobank, identified a total of only 18 loci (26–28), highlighting major

challenges in finding individual variants related to lifespan. We constructed a lifespan PRS

based on 17 of these variants (one was excluded as it was a palindromic SNP whose direction

could not be resolved) and found modest associations with all-cause mortality (HR per SD: 1.02

(0.99, 1.05) in women and 1.04 (1.02, 1.06) in men). We further constructed a new cPRS, which

included the 25 disease and risk factor PRS constructed for our analysis as well as the lifespan

PRS; the associations of this new cPRS with all-cause mortality were nearly identical to that of

the original cPRS (HR per SD of the new cPRS: 1.10 (1.05, 1.15) in women and 1.14 (1.10,

1.19) in men).

An important limitation of previous studies is the lack of adjustment for known mortality risk

factors in characterizing the potential utility of PRS for estimating mortality risk. In our analysis,

the association between the cPRS and mortality was attenuated by over 30% after adjusting for

the mortality risk factors under study. These results suggest that while genetic variants

associated with complex traits in GWAS could provide some mortality risk stratification early in

life, their utility later in life, when other risk factors for mortality can be measured, is diminished.

Most GWAS are case-control studies of disease risk as opposed to prognosis, i.e.,

aggressiveness and/or progression of the disease leading to death. When we examined the

association of the disease PRS with the corresponding cause-specific mortality among

individuals with prevalent disease in the UK Biobank (Figure S2), only the PRS for CAD and

COPD were (at least moderately) associated; in other words, for most PRS, there was little to

no evidence of an association with prognosis or disease survival. Although such analyses may

be influenced by selection associated with survivorship and poor health, in general, there is little

evidence of association between disease risk SNPs (and thus disease PRS) and survival

following disease onset. While future GWAS focusing on genetic determinants of

aggressiveness and disease progression are needed, finding associations may be challenging

due to available sample sizes and heterogeneity as a result of various factors such as

treatment.

Our analysis of the relationship between the individual PRS and all-cause mortality revealed

some important patterns (Figure 2). The strongest positive associations were seen for the PRS

for BMI, breast cancer (in women), CAD (in men), smoking status (particularly in men), and

alcohol consumption (in men). In addition, weaker associations with all-cause mortality were

seen for the PRS for Alzheimer's disease, lung cancer, and LDL cholesterol in both sexes and,

among men, associations were seen for the PRS for stroke, cirrhosis, total and HDL cholesterol,

prostate cancer, triglycerides, SBP, DBP, and type 2 diabetes. The negative association

observed among men for the triglycerides PRS appears to be driven by a strong negative

association between the triglycerides PRS and stroke-specific mortality (Figure S4), which is

consistent with the "triglycerides paradox" reported by others (63–66).

Given that the associations of the CAD PRS with CAD-specific mortality were similar for men

and women, the differences in the associations with all-cause mortality may be due to lower

rates of CAD in women during the relatively short follow-up period of the UK Biobank.

Differential event rates for some diseases for which alcohol consumption is a risk factor (e.g.,

CAD) could also partially explain the differences observed in the association of the alcohol

consumption PRS with all-cause mortality by sex. We note that the sex differences observed in

our results more generally are supported by other studies, which have similarly found

indications of differences between men and women in the mechanisms governing lifespan and

longevity (26,27,33,60,61,67,68).

Our results are generally consistent with a recent paper looking at PRS for many clinical risk

factors and mortality across the UK Biobank, a Finnish biobank (FinnGen), and Biobank Japan

(69). In this multi-ethnic study, several modest associations were observed, including for the

PRS for SBP, DBP, and BMI (HRs of around 1.03-1.04 per SD in the trans-ethnic meta-

analysis). Interestingly, the results from this analysis varied by ethnicity: for instance, within the

UK Biobank, the association between the PRS for BMI and mortality reported in Sakaue et al.

(69) was stronger than was observed in the trans-ethnic meta-analysis (HR of approximately

1.07 per SD in the UK Biobank versus 1.04 in the meta-analysis). This highlights the importance

of multi-ethnic analyses.

We evaluated the broad utility of PRS in terms of their combined ability to predict mortality. In

the future, other broad measures of health outcomes and expenditures, such as disability-

adjusted life years (DALYs), should also be considered. The framework we have created for

combining individual PRS could be used to a create composite PRS for DALYs or other

measures. Given that PRS are known to be strongly associated with incidence of many

debilitating diseases, one would anticipate such a composite PRS will have greater utility for

predicting DALYs than for mortality. However, analysis of DALYs in a cohort study with limited

follow-up, like the UK Biobank, is challenging.

Our analysis has several strengths. We used data from the UK Biobank, a large cohort study, to

carry out a comprehensive analysis of PRS for complex traits and mortality, both overall and

cause-specific. We used a novel approach to derive composite PRS across many diseases and

risk factors to evaluate their combined utility for predicting overall mortality. Under the

assumption that common genetic variants identified through recent GWAS influence mortality

risk through the outcomes underlying the GWAS, the composite PRS approach provides a more

parsimonious and powerful approach to building models for predicting composite outcomes than

building models based on individual SNPs. The weights of individual SNPs in a PRS account for

the strength and direction of association of each SNP with the corresponding outcome and the

weights for the individual PRS in the cPRS reflect (in part) the relative contribution of the

individual diseases and risk factors to mortality. Further, we conducted an unbiased evaluation

of the performance of the cPRS for predicting mortality by building it in a training dataset and

evaluating it in an independent test dataset.

As the UK Biobank participants are volunteers, there is evidence that this cohort differs from the

general UK population in important ways, including being less likely to be obese, smoke, or

drink alcohol (70). Selection bias (70), which contributes to such differences, could influence the

generalizability of our results (71). Additionally, while our cPRS include germline mutations and

so could potentially be evaluated at birth, the UK Biobank is comprised of individuals who have

survived to at least middle age. Consequently, the results may not be fully generalizable to

younger individuals and must be validated in other populations. Furthermore, the analysis of the

cPRS with adjustment for the mortality risk factors required excluding observations in the test

data with missing values for any of these risk factors. These observations constituted a

substantial portion of the test data (40.3% in women, 30.3% in men). However, as the

missingness mechanism for at least some risk factors is expected to be not random (e.g.,

individuals choosing not to answer questions regarding smoking status or alcohol consumption

due to the social stigma surrounding these behaviors), imputation is not appropriate. Thus,

some caution is warranted in interpreting these results.

As our analysis involved the evaluation of a large number of associations, issues related to

multiple comparisons are a potential concern. However, our main analysis of the cPRS was

carefully defined a priori and performed in independent test data. The other analyses we

performed were intended to check the validity of the PRS we developed and to better

understand the results of the main analysis of the cPRS. Additionally, we emphasize the

strength of association rather than statistical significance in interpreting the results throughout.

Another potential limitation of this analysis was our use of the GWAS Catalog to identify SNPs

for inclusion in the disease PRS. As the GWAS Catalog is not an exhaustive listing of SNPs

associated with every trait, we may have missed some associated SNPs. However, we believe

that our approach, which allowed us to apply a uniform procedure for SNP selection to all

diseases, captured most of the genetic susceptibility for each disease, and any differences in

the PRS would be minor. Even if our PRS included all susceptibility SNPs identified by GWAS,

the ability of the trait-specific PRS to predict all-cause mortality is related to both the power of

the GWAS as well as the genetic correlation between the trait studied in the GWAS and all-

cause mortality (72). Consequently, as GWAS continue to increase in power, we may find that

trait-specific PRS are more strongly associated with all-cause mortality. In addition, further

research on the genetic determinants of disease prognosis and survival may increase the utility

of PRS in understanding mortality risk.

In conclusion, our results suggest that by combining knowledge gained from GWAS of complex

traits, it may be possible to identify individuals who are expected to live substantially longer or

shorter. In light of the ethical repercussions of using genetics to make predictions regarding an

individual's life course at birth, we argue that the cPRS may be most useful for counselling

individuals about their genetic risk. In particular, the results of our analysis highlight the

importance of considering genetic risk in the context of clinical risk factors measured in

adulthood; thus, the cPRS may be useful in advising patients on the importance of certain

lifestyle choices associated with mortality risk. Using the cPRS in this way would require

validation of the cPRS outside of the UK Biobank.

SUPPLEMENTAL DATA DESCRIPTION

The Supplemental Data includes seven tables and five figures.

ACKNOWLEDGMENTS

This research has been conducted using the UK Biobank Resource under Application Number

17712. This research was supported by the Patient-Centered Outcomes Research Institute

(ME-1602-34530); the National Institutes of Health (1 R01 HG010480-01); and the Intramural

Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute.

DECLARATION OF INTERESTS

The authors declare no competing interests.

REFERENCES

1. Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, Yang J. 10 years of GWAS discovery: biology, function, and translation. Am J Hum Genet. 2017;101(1):5–22.

2. Zeng J, De Vlaming R, Wu Y, Robinson MR, Lloyd-Jones LR, Yengo L, Yap CX, Xue A, Sidorenko J, McRae AF, et al. Signatures of negative selection in the genetic architecture of human complex traits. Nat Genet. 2018;50(5):746–53.

3. Zhang Y, Qi G, Park JH, Chatterjee N. Estimation of complex effect-size distributions using summary-level statistics from genome-wide association studies across 32 complex traits. Nat Genet. 2018;50(9):1318–26.

4. Khera A V., Emdin CA, Drake I, Natarajan P, Bick AG, Cook NR, Chasman DI, Baber U, Mehran R, Rader DJ, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N Engl J Med. 2016;375(24):2349–58.

5. Lewis CM, Vassos E. Prospects for using risk scores in polygenic medicine. Genome Med. 2017;9(1):96.

6. Garcia-Closas M, Rothman N, Figueroa JD, Prokunina-Olsson L, Han SS, Baris D, Jacobs EJ, Malats N, De Vivo I, Albanes D, et al. Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. Cancer Res. 2013;73(7):2211–20.

7. Chatterjee N, Shi J, García-Closas M. Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nat Rev Genet. 2016;17(7):392–406.

8. Maas P, Barrdahl M, Joshi AD, Auer PL, Gaudet MM, Milne RL, Schumacher FR, Anderson WF, Check D, Chattopadhyay S, et al. Breast cancer risk from modifiable and nonmodifiable risk factors among white women in the United States. JAMA Oncol. 2016;2(10):1295–302.

9. Frampton MJE, Law P, Litchfield K, Morris EJ, Kerr D, Turnbull C, Tomlinson IP, Houlston RS. Implications of polygenic risk for personalised colorectal cancer screening. Ann

Oncol. 2016;27(3):429–34.

10.   Seibert TM, Fan CC, Wang Y, Zuber V, Karunamuni R, Parsons JK, Eeles RA, Easton

DF, Kote-Jarai Z, Al Olama AA, et al. Polygenic hazard score to guide screening for

aggressive prostate cancer: Development and validation in large scale cohorts. BMJ.

2018;360.

11.   Mavaddat N, Pharoah PDP, Michailidou K, Tyrer J, Brook MN, Bolla MK, Wang Q,

Dennis J, Dunning AM, Shah M, et al. Prediction of breast cancer risk based on profiling

with common genetic variants. J Natl Cancer Inst. 2015;107(5).

12.   Hsu L, Jeon J, Brenner H, Gruber SB, Schoen RE, Berndt SI, Chan AT, Chang-Claude J,

Du M, Gong J, et al. A model to determine colorectal cancer risk using common genetic

susceptibility loci. Gastroenterology. 2015;148(7):1330-1339.e14.

13.   Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, Nordio F, Hyde

CL, Cannon CP, Sacks FM, et al. Genetic risk, coronary heart disease events, and the

clinical benefit of statin therapy: An analysis of primary and secondary prevention trials.

Lancet. 2015;385(9984):2264–71.

14.   Natarajan P, Young R, Stitziel NO, Padmanabhan S, Baber U, Mehran R, Sartori S,

Fuster V, Reilly DF, Butterworth A, et al. Polygenic risk score identifies subgroup with

higher burden of atherosclerosis and greater relative benefit from statin therapy in the

primary prevention setting. Circulation. 2017;135(22):2091–101.

15.   Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH,

Wang Q, Bolla MK, et al. Polygenic risk scores for prediction of breast cancer and breast

cancer subtypes. Am J Hum Genet. 2019;104(1):21–34.

16.   Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk

scores. Vol. 19, Nature Reviews Genetics. Nature Publishing Group; 2018. p. 581–90.

17.   Lambert SA, Abraham G, Inouye M. Towards clinical utility of polygenic risk scores. Hum

Mol Genet. 2019;28(R2):R133–42.

18.   Wald NJ, Old R. The illusion of polygenic disease risk prediction. Genet Med.

2   2019;21(8):1705–7.

3   19.   Khera A V., Chaffin M, Wade KH, Zahid S, Brancale J, Xia R, Distefano M, Senol-Cosar

4   O, Haas ME, Bick A, et al. Polygenic prediction of weight and obesity trajectories from

5   birth to adulthood. Cell. 2019;177(3):587-596.e9.

6   20.   Langenberg C, Sharp SJ, Franks PW, Scott RA, Deloukas P, Forouhi NG, Froguel P,

7   Groop LC, Hansen T, Palla L, et al. Gene-lifestyle interaction and type 2 diabetes: the

8   EPIC InterAct case-cohort study. PLoS Med. 2014;11(5).

21.   Rudolph A, Song M, Brook MN, Milne RL, Mavaddat N, Michailidou K, Bolla MK, Wang

Q, Dennis J, Wilcox AN, et al. Joint associations of a polygenic risk score and

environmental risk factors for breast cancer in the Breast Cancer Association Consortium.

Int J Epidemiol. 2018;47(2):526–36.

22.   Hedley AJ, Wong CM, Thach TQ, Ma S, Lam TH, Anderson HR. Cardiorespiratory and

all-cause mortality after restrictions on sulphur content of fuel in Hong Kong: An

intervention study. Lancet. 2002;360(9346):1646–52.

23.   Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects

of a smoking cessation intervention on 14.5-year mortality: A randomized clinical trial.

Ann Intern Med. 2005;142(4):233–9.

24.   Grooteman MPC, Van Den Dorpel MA, Bots ML, Penne EL, Van Der Weerd NC,

Mazairac AHA, Den Hoedt CH, Van Der Tweel I, Lévesque R, Nubé MJ, et al. Effect of

online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc

Nephrol. 2012;23(6):1087–96.

25.   Mohiuddin SM, Mooss AN, Hunter CB, Grollmes TL, Cloutier DA, Hilleman DE. Intensive

smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular

disease. Chest. 2007;131(2):446–52.

26.   Timmers PR, Mounier N, Lall K, Fischer K, Ning Z, Feng X, Bretherick AD, Clark DW,

Agbessi M, Ahsan H, et al. Genomics of 1 million parent lifespans implicates novel pathways and common diseases and distinguishes survival chances. Elife. 2019;8.

27. Wright KM, Rand KA, Kermany A, Noto K, Curtis D, Garrigan D, Slinkov D, Dorfman I, Granka JM, Byrnes J, et al. A prospective analysis of genetic variants associated with human lifespan. G3. 2019;9(9):2863–78.

28. Melzer D, Pilling LC, Ferrucci L. The genetics of human ageing. Nat Rev Genet. 2019;

29. Centers for Disease Control and Prevention, National Center for Health Statistics. Underlying Cause of Death 1999-2017 on CDC WONDER Online Database [Internet]. Available from: http://wonder.cdc.gov/ucd-icd10.html

30. Office for National Statistics. Mortality statistics - underlying cause, sex and age [Internet]. Nomis. Available from: https://www.nomisweb.co.uk/datasets/mortsa

31. Public Health England. Major causes of death and how they have changed [Internet]. Available from: https://www.gov.uk/government/publications/health-profile-for-england/chapter-2-major-causes-of-death-and-how-they-have-changed

32. Ganna A, Rivadeneira F, Hofman A, Uitterlinden AG, Magnusson PKE, Pedersen NL, Ingelsson E, Tiemeier H. Genetic determinants of mortality. Can findings from genome-wide association studies explain variation in human mortality? Hum Genet. 2013;132(5):553–61.

33. Joshi PK, Pirastu N, Kentistou KA, Fischer K, Hofer E, Schraut KE, Clark DW, Nutile T, Barnes CLK, Timmers PRHJ, et al. Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevity. Nat Commun. 2017;8.

34. Da Silva AA, De Mello RGB, Schaan CW, Fuchs FD, Redline S, Fuchs SC. Sleep duration and mortality in the elderly: A systematic review with meta-analysis. BMJ Open. 2016;6(2).

35. Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause mortality: A systematic review and meta-analysis of prospective studies. Sleep. 2010;33(5):585–92.

36. Liu TZ, Xu C, Rota M, Cai H, Zhang C, Shi MJ, Yuan RX, Weng H, Meng XY, Kwong
JSW, et al. Sleep duration and risk of all-cause mortality: A flexible, non-linear, meta-
regression of 40 prospective cohort studies. Sleep Med Rev. 2017;32:28–36.
37. Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, McMahon A,
Morales J, Mountjoy E, Sollis E, et al. The NHGRI-EBI GWAS Catalog of published
genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic
Acids Res. 2019;47(D1):D1005–12.
38. Hunt SE, McLaren W, Gil L, Thormann A, Schuilenburg H, Sheppard D, Parton A,
Armean IM, Trevanion SJ, Flicek P, et al. Ensembl variation resources. Database.
2018;2018.
39. Rutten-Jacobs LCA, Larsson SC, Malik R, Rannikmäe K, Sudlow CL, Dichgans M,
Markus HS, Traylor M. Genetic risk, incident stroke, and the benefits of adhering to a
healthy lifestyle: Cohort study of 306 473 UK Biobank participants. BMJ. 2018;363.
40. Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, Datta G, Davila-Velderrain J,
McGuire D, Tian C, et al. Association studies of up to 1.2 million individuals yield new
insights into the genetic etiology of tobacco and alcohol use. Nat Genet. 2019;51(2):237–
44.
41. UK Biobank — Neale lab [Internet]. Available from: http://www.nealelab.is/uk-biobank
42. Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, Frayling TM,
Hirschhorn J, Yang J, Visscher PM, et al. Meta-analysis of genome-wide association
studies for height and body mass index in □700,000 individuals of European ancestry.
Hum Mol Genet. 2018;27(20):3641–9.
43. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, Ganna A,
Chen J, Buchkovich ML, Mora S, et al. Discovery and refinement of loci associated with
lipid levels. Nat Genet. 2013;45(11):1274–85.
44. Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, MäGi R, Strawbridge

RJ, Rehnberg E, Gustafsson S, et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet. 2012;44(9):991–1005.

45. Li M, Li Y, Weeks O, Mijatovic V, Teumer A, Huffman JE, Tromp G, Fuchsberger C, Gorski M, Lyytikäinen LP, et al. SOS2 and ACP1 loci identified through large-scale exome chip analysis regulate kidney development and function. J Am Soc Nephrol. 2017;28(3):981–94.

46. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779.

47. Eastwood S V., Mathur R, Atkinson M, Brophy S, Sudlow C, Flaig R, De Lusignan S, Allen N, Chaturvedi N. Algorithms for the capture and adjudication of prevalent and incident diabetes in UK Biobank. PLoS One. 2016;11(9).

48. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira M, Bender D, Maller J, Sklar P, de Bakker P, Daly M, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559–75.

49. Auton A, Abecasis GR, Altshuler DM, Durbin RM, Bentley DR, Chakravarti A, Clark AG, Donnelly P, Eichler EE, Flicek P, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74.

50. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702–6.

51. Levey AS, De Jong PE, Coresh J, Nahas M El, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU. The definition, classification, and prognosis of chronic kidney disease: A KDIGO Controversies Conference report. Kidney Int. 2011;80(1):17–28.

52. Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests.

JAMA. 1982;247(18):2543–6.

53. R Core Team. R: A language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2019. Available from: https://www.r-project.org/

54. Harrell FE. rms: Regression Modeling Strategies [Internet]. 2019. Available from: https://cran.r-project.org/package=rms

55. Therneau T. A package for survival analysis in S. 2015.

56. Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York: Springer-Verlag; 2016.

57. Zeileis A. Econometric computing with HC and HAC covariance matrix estimators. J Stat Softw. 2004;11(10):1–17.

58. Zeileis A. Object-oriented computation of sandwich estimators. J Stat Softw. 2006;16(9):1–16.

59. Mostafavi H, Berisa T, Day FR, Perry JRB, Przeworski M, Pickrell JK. Identifying genetic variants that affect viability in large cohorts. PLoS Biol. 2017;15(9).

60. Pilling LC, Atkins JL, Bowman K, Jones SE, Tyrrell J, Beaumont RN, Ruth KS, Tuke MA, Yaghootkar H, Wood AR, et al. Human longevity is influenced by many genetic variants: evidence from 75,000 UK Biobank participants. Aging (Albany NY). 2016;8(3):547–60.

61. Pilling LC, Kuo C-L, Sicinski K, Tamosauskaite J, Kuchel GA, Harries LW, Herd P, Wallace R, Ferrucci L, Melzer D. Human longevity: 25 genetic loci associated in 389,166 UK biobank participants. Aging (Albany NY). 2017;9(12):2504–20.

62. Marioni RE, Ritchie SJ, Joshi PK, Hagenaars SP, Okbay A, Fischer K, Adams MJ, Hill WD, Davies G, Social Science Genetic Association Consortium, et al. Genetic variants linked to education predict longevity. Proc Natl Acad Sci U S A. 2016;113(47):13366–71.

63. Dziedzic T, Slowik A, Gryz EA, Szczudlik A. Lower serum triglyceride level is associated with increased stroke severity. Stroke. 2004;35(6).

64. Jain M, Jain A, Yerragondu N, Brown RD, Rabinstein A, Jahromi BS, Vaidyanathan L,

Blyth B, Stead LG. The triglyceride paradox in stroke survivors: A prospective study.

Neurosci J. 2013;2013.

65. Ryu WS, Lee SH, Kim CK, Kim BJ, Yoon BW. Effects of low serum triglyceride on stroke

mortality: A prospective follow-up study. Atherosclerosis. 2010;212(1):299–304.

66. Li W, Liu M, Wu B, Liu H, Wang LC, Tan S. Serum lipid levels and 3-month prognosis in

Chinese patients with acute stroke. Adv Ther. 2008;25(4):329–41.

67. Beekman M, Blanché H, Perola M, Hervonen A, Bezrukov V, Sikora E, Flachsbart F,

Christiansen L, De Craen AJM, Kirkwood TBL, et al. Genome-wide linkage analysis for

human longevity: Genetics of Healthy Aging Study. Aging Cell. 2013;12(2):184–93.

68. Joshi PK, Fischer K, Schraut KE, Campbell H, Esko T, Wilson JF. Variants near

CHRNA3/5 and APOE have age- and sex-related effects on human lifespan. Nat

Commun. 2016;7.

69. Sakaue S, Kanai M, Karjalainen J, Akiyama M, Kurki M, Matoba N, Takahashi A, Hirata

M, Kubo M, Matsuda K, et al. Trans-biobank analysis with 676,000 individuals elucidates

the association of polygenic risk scores of complex traits with human lifespan. Nat Med.

2020.

70. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, Collins R, Allen NE.

Comparison of sociodemographic and health-related characteristics of UK Biobank

participants with those of the general population. Am J Epidemiol. 2017;186(9):1026–34.

71. Keyes KM, Westreich D. UK Biobank, big data, and the consequences of non-

representativeness. Lancet. 2019 Mar 30;393(10178):1297.

72. Krapohl E, Patel H, Newhouse S, Curtis CJ, Von Stumm S, Dale PS, Zabaneh D, Breen

G, O'Reilly PF, Plomin R. Multi-polygenic score approach to trait prediction. Mol

Psychiatry. 2018;23(5):1368–74.

FIGURE TITLES AND LEGENDS

**Figure 1: Association of each disease PRS with cause-specific mortality in the full
cohort.** For each disease, we evaluated the association between the disease PRS and mortality
from the disease based on sex-specific Cox proportional hazards models of age at death.
Deaths from other causes were treated as censoring events. Some causes did not have enough
deaths to yield stable estimates, i.e., < 6 deaths; in these cases, estimates are not provided.
Each PRS was standardized to have unit variance so the estimates correspond to the HR per
SD of the PRS. The horizontal lines indicate 95% confidence intervals. CAD: coronary artery
disease; COPD: chronic obstructive pulmonary disease; HR: hazard ratio; SD: standard
deviation; PRS: polygenic risk score.
11
Figure 2: Association of each trait-specific PRS with all-cause mortality in the full cohort.
We evaluated the association between each PRS and all-cause mortality based on sex-specific
Cox proportional hazards models of age at death in the full cohort. Each Cox model included
one PRS. Each PRS was standardized to have unit variance so the estimates correspond to the
HR per SD of the PRS. The horizontal lines indicate 95% confidence intervals. BMI: body mass
index; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; DBP:
diastolic blood pressure; eGFR: estimated glomerular filtration rate; HDL: high-density
lipoprotein; LDL: low-density lipoprotein; SBP: systolic blood pressure; HR: hazard ratio; SD:
standard deviation; PRS: polygenic risk score.
21
22 **Figure 3: Kaplan-Meier survival curves by quantile of the cPRS.** We estimated the sex-
23 specific Kaplan-Meier survival curves for all-cause mortality by quantile of the cPRS in the test
24 data. The Kaplan-Meier curves do not include adjustment for principal components. cPRS:
25 composite polygenic risk score.
26
**Figure 4: Estimates of absolute risk of mortality in different strata of the cPRS for
specific categories of BMI and smoking status.** We generated estimates of 10-year absolute
risk of all-cause mortality for a 60-year-old in different strata of the cPRS for specific values of
two mortality risk factors, BMI and smoking status. Panels A and B correspond to the results in
women (for BMI and smoking status, respectively) and panels C and D correspond to the results
in men (for BMI and smoking status, respectively). The horizontal line in each plot corresponds
to an estimate of 10-year absolute risk of all-cause mortality for a 60-year-old in the middle
quintile of the cPRS, based on sex-specific Cox proportional hazards models with quintiles of
the cPRS, modeled as a categorical variable, fit in the test data. BMI: body mass index; cPRS:
composite polygenic risk score.

TABLE TITLES AND LEGENDS

Table 1: Descriptive statistics. Descriptive statistics for the full cohort used for the analysis
(after removing individuals who were related, were not of British ancestry, or had withdrawn
their consent to participate), the training data (2/3 of the full cohort), and the test data (1/3 of the
full cohort).

	Full cohort		Training data		Test data	
	Women	Men	Women	Men	Women	Men
Sample size	181,027	156,111	120,719	104,037	60,308	52,074
Age at study entry (years; mean (SD))	57.2 (7.9)	57.6 (8.1)	57.2 (7.9)	57.6 (8.1)	57.2 (7.9)	57.6 (8.1)
Follow-up (years; mean (SD))	8.8 (1.1)	8.7 (1.3)	8.8 (1.1)	8.7 (1.3)	8.8 (1.0)	8.7 (1.3)
Number of deaths	5,250	8,360	3,530	5,576	1,720	2,784

6   SD: standard deviation.

Table 2: The results of the main analysis of all-cause mortality and the cPRS, with and
without adjustment for mortality risk factors. The cPRS were constructed in the training data
and evaluated by fitting sex-specific Cox proportional hazards models of the association
between the cPRS and age at death from all causes in the test data. Both the continuous cPRS
and categorical cPRS were modeled. The estimated HRs and CIs were converted to estimated
years of life lost. The analysis adjusting for mortality risk factors included adjustment for the risk
factors measured at baseline (BMI, smoking status, alcohol consumption, SBP, DBP, eGFR,
total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, blood glucose, and sleep
duration); individuals missing any of these measurements were excluded.

	Women	Men
Without adjustment for mortality risk factors		
Population in test data: N (deaths)		
Total population	60,308 (1,720)	52,074 (2,784)
Top 5% of cPRS	3,060 (107)	2,454 (159)
Middle 20% of cPRS	12,005 (342)	10,387 (539)
Bottom 5% of cPRS	3,096 (69)	2,526 (89)
cPRS: HR (95% CI)		
Per SD of cPRS	1.10 (1.05, 1.16)	1.15 (1.10, 1.19)
Top 5% vs. middle 20% of cPRS	1.24 (1.00, 1.54)	1.27 (1.07, 1.52)
Bottom 5% vs. middle 20% of cPRS	0.77 (0.59, 1.00)	0.65 (0.52, 0.81)
Top 5% vs. bottom 5% of cPRS	1.61 (1.19, 2.18)	1.96 (1.52, 2.55)
cPRS: years of life lost (95% CI)		
Per SD of cPRS	0.97 (0.50, 1.44)	1.36 (0.98, 1.73)
Top 5% vs. middle 20% of cPRS	2.17 (0.00, 4.34)	2.42 (0.65, 4.19)
Bottom 5% vs. middle 20% of cPRS	-2.61 (-5.20, -0.03)	-4.33 (-6.58, -2.09)
Top 5% vs. bottom 5% of cPRS	4.79 (1.76, 7.81)	6.75 (4.16, 9.35)
With adjustment for mortality risk factors		
Population in test data: N (deaths)		
Total population	36,008 (855)	36,283 (1,730)
Top 5% of cPRS	1,799 (51)	1,689 (102)
Middle 20% of cPRS	7,143 (168)	7,240 (329)
Bottom 5% of cPRS	1,907 (37)	1,804 (60)
cPRS: HR (95% CI)		
Per SD of cPRS	1.06 (0.99, 1.13)	1.10 (1.04, 1.15)
Top 5% vs. middle 20% of cPRS	1.19 (0.87, 1.63)	1.25 (1.00, 1.56)
Bottom 5% vs. middle 20% of cPRS	0.88 (0.62, 1.26)	0.73 (0.55, 0.96)
Top 5% vs. bottom 5% of cPRS	1.35 (0.88, 2.07)	1.71 (1.24, 2.36)
cPRS: years of life lost (95% CI)		
Per SD of cPRS	0.58 (-0.11, 1.26)	0.92 (0.43, 1.40)
Top 5% vs. middle 20% of cPRS	1.72 (-1.43, 4.86)	2.20 (-0.03, 4.43)
Bottom 5% vs. middle 20% of cPRS	-1.27 (-4.85, 2.30)	-3.19 (-5.95, -0.43)
Top 5% vs. bottom 5% of cPRS	2.99 (-1.28, 7.26)	5.39 (2.18, 8.60)

10 BMI: body mass index; CI: confidence interval; cPRS: composite polygenic risk score; DBP:
11 diastolic blood pressure; eGFR: estimated glomerular filtration rate; HDL: high-density
12 lipoprotein; HR: hazard ratio; LDL: low-density lipoprotein; SBP: systolic blood pressure; SD:
13 standard deviation.